Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Morphine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 6/20 | 0.75 |
| ▸ | OPRD1 | P41143 | 8/20 | 0.75 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.75 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 0.75 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.75 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.75 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Morphine SCHEMBL3476234 | 1.00 | OPRD1 (0.75) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL30301300 | 0.92 | OPRD1 (0.85) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL16635671 | 0.91 | OPRD1 (0.85) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL7492942 | 0.90 | OPRD1 (0.70) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Codeine SCHEMBL7770906 | 0.90 | OPRM1 (0.77) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Codeine SCHEMBL3477475 | 0.90 | OPRM1 (0.77) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Codeine SCHEMBL7775792 | 0.90 | OPRM1 (0.77) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL29223948 | 0.89 | OPRD1 (0.79) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL149700 | 0.88 | OPRD1 (0.90) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL15055206 | 0.88 | OPRD1 (0.90) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220096460-A1 | ABUSE-RESISTANT LONG-ACTING RELEASE OPIOID PRODRUGS | SUZHOU RUNXINDATAI PHARMACEUTICS LTD CO. (CN) | 2022-03-31 | — | — | US | disclosed |
| EP-3911321-A1 | ABUSE-RESISTANT LONG-ACTING RELEASE OPIOID PRODRUGS | Suzhou Runxindatai Pharmaceutics Ltd Co. (CN) | 2021-11-24 | — | — | EP | disclosed |
| CN-113543785-A | Abuse resistant extended release opioid prodrugs | 苏州润鑫达泰生物医药有限公司 | 2021-10-22 | — | — | CN | disclosed |
| WO-2020150414-A1 | ABUSE-RESISTANT LONG-ACTING RELEASE OPIOID PRODRUGS | SUZHOU RUNXINDATAI PHARMACEUTICS LTD CO. (CN) | 2020-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220096460-A1 | ABUSE-RESISTANT LONG-ACTING RELEASE OPIOID PRODRUGS | OPRK1, OPRM1, OPRL1 | OPRM1 2/4885OPRD1 4/4885OPRK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.